跳至主要内容
临床试验/NCT01230541
NCT01230541已完成1 期

Effect of Udenafil on Spermatogenesis: A Double-blind, Randomized, Placebo-controlled, Parallel-group Study

Warner Chilcott1 个研究点 分布在 1 个国家目标入组 239 人开始时间: 2010年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
239
试验地点
1
主要终点
Sperm Concentration Reduction greater than or equal to 50% at Week 26

研究概览

简要总结

Study of udenafil daily in subjects with mild or no erectile dysfunction to evaluate effects on semen characteristics.

详细描述

Safety Study in male subjects with no or mild ED (erectile dysfunction)

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
25 Years 至 64 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • No or mild ED (erectile dysfunction) willing & able to provide 2 semen samples without the use of PDE-5 inhibitor or other excluded medication or devices on 2 separate days during screening and at Weeks 12 & 26
  • BMI (body mass index) between 19 and 31 kilogram/meter squared

排除标准

  • New onset coronary artery disease within last 3 months, history of myocardial infarction or cardiac surgical procedure within last 6 months or sudden cardiac arrest
  • Nitrate medications for angina pectoris
  • Used of anti-arrhythmic drug treatment or device
  • Congestive heart failure
  • Uncontrolled diabetes
  • Stroke or transient ischemic attack (TIA) within last 6 months
  • Bleeding disorder or history of GI bleeding within last 12 months
  • Cancer chemotherapy
  • History of alcohol or drug abuse

研究组 & 干预措施

Placebo

Placebo Comparator

Placebo

干预措施: Placebo (Drug)

Udenafil

Active Comparator

Udenafil daily tablet

干预措施: Udenafil (Drug)

结局指标

主要结局

Sperm Concentration Reduction greater than or equal to 50% at Week 26

时间窗: 26 weeks

Percentage of Subjects with greater than or equal to 50% decrease from baseline in sperm concentration at 26 weeks

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验